Medical-device makers ResMed and Inspire slump after Lilly's Zepbound trial shows benefits for sleep apneaMarket Watch • 06/24/24
Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — AgainInvestors Business Daily • 06/24/24
Weight-loss drug Zepbound resolves sleep apnea in up to 52% of patients, Lilly saysReuters • 06/21/24
Lilly's tirzepatide reduced obstructive sleep apnea (OSA) severity, with up to 51.5% of participants meeting the criteria for disease resolutionPRNewsWire • 06/21/24
Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the yearCNBC • 06/21/24
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to NoteZacks Investment Research • 06/20/24
How Eli Lilly is managing soaring demand for GLP-1s, according to outgoing CFO Anat AshkenaziCNBC • 06/17/24
8 stocks other than Microsoft, Apple and Nvidia that could be worth $4 trillion in three yearsMarket Watch • 06/17/24
Thinking of Buying Madrigal Pharmaceuticals Stock? Eli Lilly Would Like to Have a Word.The Motley Fool • 06/16/24